Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 7,024 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Volunteers. Clear all

Conditions: Alzheimer Disease
Interventions: Donepezil, BMS-708163; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: FOS; Dietary Supplement
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Healthy Volunteer
Interventions: Tavapadon; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Cancer, Healthy
Interventions: Cooked parsnips with parsley; Dietary Supplement
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy, Opioid-induced Constipation
Interventions: TD-1211, Placebo; Drug
Lead sponsor: Glycyx Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 3
States / cities: Pasadena, California • San Antonio, Texas • Salt Lake City, Utah

Conditions: Renal Impairment
Interventions: Lemborexant; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Healthy
Interventions: Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg, Benicar HCT® Tablets 40 mg/25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alzheimer's Disease
Interventions: LY2811376, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Infections, Bacterial
Interventions: GSK1322322; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy Volunteers
Interventions: SPD422, Omeprazole; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC /VI, UMEC, VI, FF; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: AIR645, Physiologic saline solution; Drug
Lead sponsor: Altair Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Psoriasis
Interventions: ABBV-553, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 4
States / cities: Anaheim, California • Toluca, California • Port Orange, Florida + 1 more

Conditions: Tolerance
Interventions: 1 serving of test product, 2 servings of test product, 3 servings of test product, Placebo; Other
Lead sponsor: Liquid I.V.; Other
Eligibility: 18 Years to 35 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Anticoagulant Reversal
Interventions: Fresh Frozen Plasma (FFP), Freeze Dried Plasma (FDP); Biological
Lead sponsor: Teleflex; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Malaria
Interventions: AMA1/Alhydrogel; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aphasia, Cerebrovascular Accident
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: IPF
Interventions: HNC1058 Capsules; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: Almorexant, Zolpidem 10mg, Placebo; Drug
Lead sponsor: Northern California Institute of Research and Education; Other
Eligibility: 19 Years to 39 Years
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Asthma, Hypersensitivity
Interventions: Clinical Center Reference Endotoxin (CCRE); Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Participants
Interventions: Compression Boots; Device
Lead sponsor: University of Redlands; Other
Eligibility: 18 Years to 23 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Redlands, California

Conditions: Safety and Tolerability
Interventions: MDI-2517, Placebo; Drug · Other
Lead sponsor: MDI Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: V350A, V350B, Placebo; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Years to 30 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Glendale, California • South Miami, Florida • Kansas City, Missouri + 6 more

Search by objective public record fields.

Drug-Drug Interaction Study With Aricept® (Donepezil)

A Study to Evaluate the Effect of Diet on the Tolerability of FOS in Healthy Volunteers

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

Development of a Biomarker for Dietary Furanocoumarins

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

Neural Correlates of Observation of Tactile Stimulation in Healthy Subjects

A Safety Study of LY2811376 Single Doses in Healthy Subjects

Relative Bioavailability Study in Healthy Subjects

Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants

A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

Clinical Trial to Evaluate Safety and Tolerability of a Novel Hydration Drink in Healthy Volunteers

Clinical Trial Assessing Non-Inferiority of Freeze Dried Plasma to Fresh Frozen Plasma in Reversing Warfarin

Experimental Vaccine for Malaria

Role of the Right Brain in Recovery of Language Function in Chronic Stroke

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance

A Study of Inhalation of 20,000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals

The Effects of Recovery Compression Boots on Blood Lactate Levels, Functional Movement, and Joint Ange of Motion in Collegiate Athletes.

SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).